胃炎は、胃の粘膜の炎症または腫れを特徴とします。急性胃炎は短期間、慢性胃炎は長期間（数ヶ月から数年）続きます。胃炎は、イブプロフェン、アスピリン、ナプロキセンなどの薬の長期服用、アルコールの過剰摂取、ヘリコバクターピロリ感染、特定の自己免疫疾患、胆汁逆流、薬物乱用（コカイン）、毒物などの腐食・腐蝕物質の摂取、強いストレス、ウイルス感染、外傷などによって引き起こされることがあります。胃炎の症状には、食欲不振、吐き気、嘔吐、腹痛、黒色便などがあります。治療には、制酸薬、ヒスタミン2（H2）拮抗薬、プロトンポンプ阻害薬などが使用されます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastritis - Overview
Gastritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Gastritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastritis - Companies Involved in Therapeutics Development
Gastritis - Drug Profiles
Gastritis - Dormant Projects
Gastritis - Product Development Milestones
Featured News & Press Releases
Dec 08, 2020: Rebamipid, which has risen in price, imminent commercialization of domestically developed western-release tablets
Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting
Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis
Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Gastritis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Gastritis - Pipeline by Addpharma Inc, 2022
Gastritis - Pipeline by CalyGene Biotechnology Inc, 2022
Gastritis - Pipeline by Daewon Pharmaceutical Co Ltd, 2022
Gastritis - Pipeline by Daewoong Co Ltd, 2022
Gastritis - Pipeline by GNT Pharma Co Ltd, 2022
Gastritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Gastritis - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2022
Gastritis - Pipeline by Kyowa Kirin Co Ltd, 2022
Gastritis - Pipeline by Marinomed Biotech AG, 2022
Gastritis - Pipeline by Oncostellae SL, 2022
Gastritis - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Gastritis - Pipeline by Recce Pharmaceuticals Ltd, 2022
Gastritis - Pipeline by RedHill Biopharma Ltd, 2022
Gastritis - Pipeline by Trio Medicines Ltd, 2022
Gastritis - Dormant Projects, 2022
List of Figures
Number of Products under Development for Gastritis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
